Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study

Table 2 Univariate Analyses

Characteristic	OS			DFS			LRRFS			DMFS
Characteristic	No.	5Y (%)	p-value	No.	5Y (%)	p-value	No.	5Y (%)	p-value	No.	5Y (%)	p-value
Sex
Male	523	80	0.082	521	73	0.037	525	86	0.025	522	91	0.787
Female	63	90		63	88		63	94		63	91
Age (years)
< 60	395	85	<0.001	393	80	<0.001	395	89	0.121	394	92	0.026
≥ 60	189	73		189	62		189	83		189	86
Smoking history
Never/ex-smoker	330	85	0.001	329	79	0.001	330	90	0.005	330	92	0.306
Current smoker	206	76		205	67		206	82		205	89
Performance status
ECOG 0	197	85	0.094	197	80	0.027	197	93	0.008	197	92	0.45
ECOG 1–2	372	79		370	72		372	85		371	90
PET/CT
No	182	79	0.226	181	74	0.847	182	88	0.669	182	93	0.311
Yes	404	83		403	74		404	87		403	89
T stage
T1–T2	426	87	<0.001	425	81	<0.001	426	90	0.003	425	94	<0.001
T3–T4	160	67		159	58		160	81		160	82
N stage
N0–N2b	504	84	0.005	503	78	<0.001	504	88	0.055	504	83	<0.001
N2c–N3	82	67		81	55		82	81		81	79
Stage
I–III	132	90	0.066	132	85	0.016	132	93	0.06	132	97	0.004
IVA–IVB	454	79		452	72		454	86		453	89
Chemotherapy
Concurrent/no	525	83	<0.001	523	76	0.006	525	88	0.263	524	90	0.762
Induction	61	71		61	64		61	83		61	93
Radiotherapy technique
3D–CRT	391	80	0.420	389	74	0.36	391	87	0.754	390	90	0.235
IMRT	194	84		194	76		194	88		194	92
Treatment modality
CRT	201	82	0.698	201	78	0.612	201	89	0.695	201	94	0.157
SRT	385	81		383	73		385	87		384	89

Abbreviations: OS overall survival, DFS disease-free survival, LRRFS locoregional recurrence-free survival, DMFS distant metastasis-free survival, ECOG Eastern Cooperative Oncology Group, PET/CT positron emission tomography–computed tomography, 3D–CRT three-dimensional conformal radiotherapy, IMRT intensity modulated radiotherapy, CRT radiotherapy with chemotherapy, SRT surgery followed by radiotherapy

ISSN: 1471-2407